长效抗逆转录病毒药物:HIV感染管理与预防的新时代
综述指出长效卡博特韦与利匹韦林组合已获FDA、EMA和加拿大卫生部批准,将每日口服负担降至每年六次肌注;Islatravir植入剂给药间隔可达一年以上。目前LA-ARTs采用固定标准剂量,未考虑体重、BMI及宿主因素,个体间药代动力学变异显著,治疗药物监测(TDM)可提供实际药物暴露信息。
要点
- 长效卡博特韦+利匹韦林组合已获批,每年仅需六次肌注。
- Islatravir植入剂给药间隔可达一年或更长。
- LA-ARTs固定剂量未考虑体重、BMI及宿主因素,TDM可辅助精准管理。
核心结论
- 长效抗逆转录病毒疗法(LA-ARTs)的发展与实施可通过改善患者隐私和减少每日口服抗HIV治疗相关的社会污名化来克服长期依从性问题。
研究设计与样本
- 本文为综述,旨在更新新型LA-ARTs的知识现状,并从临床药代动力学角度讨论其对HIV感染未来管理和预防的意义。
主要发现
- 长效卡博特韦和利匹韦林组合已将365天每日服药负担减少至每年仅六次肌内注射。
- Islatravir作为首创核苷逆转录酶易位抑制剂,拟配制成给药间隔为1年或更长的植入剂。
- 当前LA-ARTs按固定标准剂量给药,不考虑患者体重和BMI,也未考虑可能影响其全身处置的宿主遗传和非遗传因素。
关键数值与推荐
- 长效卡博特韦和利匹韦林组合已获FDA、EMA和加拿大卫生部批准。
- Islatravir植入剂拟给药间隔为1年或更长。
临床怎么用
- 治疗药物监测(TDM)作为精准医学工具,可为医生提供患者实际药物暴露的信息,有助于改善真实世界中的管理。
局限性
- LA-ARTs仍存在给药相关挑战(如疼痛、专门医疗操作)。
- 当前「一刀切」方法未考虑LA-ART药代动力学的显著个体间变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA, EMA and Health Canada approval. This novel drug delivery approach is about to revolutionize the therapy of people living with HIV, decreasing the 365 daily pill burden to only six intramuscular injections per year. In addition, islatravir, a first-in-class nucleoside reverse transcriptase translocation inhibitor, is intended to be formulated as an implant with a dosing interval of 1 year or more. At present, long-acting antiretroviral therapies (LA-ARTs) are given at fixed standard doses, irrespectively of the patient's weight and BMI, and without consideration for host genetic and non-genetic factors likely influencing their systemic disposition. Despite a few remaining challenges related to administration (e.g. pain, dedicated medical procedure), the development and implementation of LA-ARTs can overcome long-term adherence issues by improving patients' privacy and reducing social stigma associated with the daily oral intake of anti-HIV treatments. Yet, the current 'one-size-fits-all' approach does not account for the recognized significant inter-individual variability in LA-ART pharmacokinetics. Therapeutic drug monitoring (TDM), an important tool for precision medicine, may provide physicians with valuable information on actual drug exposure in patients, contributing to improve their management in real life. The present review aims to update the current state of knowledge on these novel promising LA-ARTs and discusses their implications, particularly from a clinical pharmacokinetics perspective, for the future management and prevention of HIV infection, issues of ongoing importance in the absence of curative treatment or an effective vaccine.
引用
- Thoueille P, Choong E, Cavassini M, et al. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022. PMID: 34499731. doi:10.1093/jac/dkab324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。